

Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"

(HIC# 1006007008)

TrialNet investigators want to see if an experimental medication called **teplizumab** may stop or slow down the autoimmune reaction that is destroying beta cells in people who are at high risk of developing type 1 diabetes. In this study, we will compare people who get infusions of teplizumab with those who get infusions that look the same but have no teplizumab, called **placebo**. Teplizumab is given through an intravenous (IV) infusion. The infusions are given daily for 14 days and last 30 minutes. Each visit takes about 4 hours. Follow up visits occur at various intervals.

You can be screened for this study if:

You are 8-45 years old

The tests you took in the Natural History study showed that you are at high risk for developing type 1 diabetes

For more information, contact Laurie Feldman (203) 737-2760 or laurie.feldman@yale.edu